linezolid sandoz solution for infusion 2mg ml - search results

Australia - English - Department of Health (Therapeutic Goods Administration)

linezolid myx linezolid 600 mg/300 ml injection infusion bag

mayne pharma international pty ltd - linezolid -

Australia - English - Department of Health (Therapeutic Goods Administration)

linevox linezolid 600mg tablet blister pack

arrotex pharmaceuticals pty ltd - linezolid, quantity: 600 mg - tablet, film coated - excipient ingredients: lactose monohydrate; povidone; microcrystalline cellulose; magnesium stearate; purified talc; poloxamer; colloidal anhydrous silica; sodium starch glycollate type a; propylene glycol; brilliant blue fcf; ethanol; purified water; shellac; strong ammonia solution; titanium dioxide; hypromellose; macrogol 400 - linezolid is indicated for the treatment of suspected or proven infections due to gram positive organisms resistant to multiple classes of antibiotics, including methicillin resistant staphylococcus species and vancomycin resistant enterococcus species. ,linezolid is active against gram-positive bacteria only. linezolid has no clinical activity against gram-negative pathogens. specific gram-negative therapy is required if a concomitant gram-negative pathogen is documented or suspected

United States - English - NLM (National Library of Medicine)

linezolid tablet film coated

american health packaging - linezolid (unii: isq9i6j12j) (linezolid - unii:isq9i6j12j) - linezolid 600 mg

United States - English - NLM (National Library of Medicine)

linezolid injection solution

teva parenteral medicines, inc. - linezolid (unii: isq9i6j12j) (linezolid - unii:isq9i6j12j) - linezolid 2 mg in 1 ml

Australia - English - Department of Health (Therapeutic Goods Administration)

fentanyl sandoz fentanyl 25 micrograms/hour transdermal drug delivery system sachet

sandoz pty ltd - fentanyl, quantity: 4.2 mg - drug delivery system, transdermal - excipient ingredients: polyethylene terephthalate; ethyl acetate; 2-ethylhexyl acrylate; vinyl acetate; 2,2'-azobisisobutyronitrile; 2-hydroxyethyl acrylate - for the management of pain associated with cancer, palliative cancer and other conditions in patients where: - other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain, and - the pain is opioid-responsive, and - severe enough to require daily, continuous long term opioid treatment. not for use in opioid-naive patients.